Tuberculosis risk varies with the duration of HIV infection: A prospective study of European drug users with known date of HIV seroconversion

AIDS

Volumn 17, Issue 8, 2003, Pages 1201-1208

  Van Asten, Liselotte ^a   Langendam, Miranda ^a   Zangerle, Robert ^b   Aguado, Ildefonso Hernández ^c   Boufassa, Faroudy ^d   Schiffer, Veronique ^e   Brettle, Raymond P ^f   Robertson, J Roy ^g   Fontanet, Arnaud ^a   Coutinho, Roel A ^a,h   Prins, Maria ^a  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^d BICÊTRE HOSPITAL   (France)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f WESTERN GENERAL HOSPITAL   (United Kingdom)

^g Edinburgh Drug Addiction Study   (United Kingdom)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Europe; HIV infection; Incidence; Intravenous drug users; Longitudinal studies; Risk factors; Tuberculosis

Indexed keywords

CD4 ANTIGEN;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE DURATION; DRUG USE; EUROPE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GEOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; INJECTION; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; POISSON DISTRIBUTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK FACTOR; SEROCONVERSION; SPAIN; T LYMPHOCYTE; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; EUROPE; FEMALE; FOLLOW-UP STUDIES; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MALE; POISSON DISTRIBUTION; PROSPECTIVE STUDIES; RISK FACTORS; STATISTICS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; TUBERCULOSIS;

EID: 0037980412     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305230-00012     Document Type: Article

References (34)

1. Cowley S. The biology of HIV infection. Lepr Rev 2001, 72:212-220.
2. Bocchino M, Sanduzzi A, Bariffi F. Mycobacterium tuberculosis and HIV co-infection in the lung: synergic immune dysregulation leading to disease progression. Monaldi Arch Chest Dis 2000, 55:381-388.
3. Redpath S, Ghazal P, Gascoigne NR. Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol 2001, 9:86-92.
4. Corbett EL, de Cock KM. Tuberculosis in the HIV-positive patient. Br J Hosp Med 1996, 56:200-204.
5. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999, 340:367-373.
6. Castilla J, Gutiérrez A, Guerra L, Pérez de la Paz J, Noguer I, Ruiz C, et al. Pulmonary and extrapulmonary tuberculosis at AIDS diagnosis in Spain: epidemiological differences and implications for control. AIDS 1997, 11:1583-1588.
7. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995, 274:143-148.
8. Jones JL, Hanson DL, Dworkin MS, DeCock KM. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 2000, 4:1026-1031.
9. Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000, 23:75-80.
10. Mukadi Y, Perriens JH, St Louis ME, Brown C, Prignot J, Willame JC, et al. Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire. Lancet 1993, 342:143-146.
11. Girardi E, Antonucci G, Armignacco O, Salmaso S, Ippolito G. Tuberculosis and AIDS: a retrospective, longitudinal, multicentre study of Italian AIDS patients. Italian Group for the Study of Tuberculosis and AIDS (GISTA). J Infect 1994, 28:261-269.
12. Keizer ST, Langendam MM, van Deutekom H, Coutinho RA, van Ameijden EJ. How does tuberculosis relate to HIV positive and HIV negative drug users? J Epidemiol Community Health 2000, 54:64-68.
13. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989, 320:545-550.
14. Markowitz N, Hansen NI, Hopewell PC, Gkassroth J, Kvale PA, Mangura BT, et al. Incidence of tuberculosis in the United States among HIV-infected persons. The Pulmonary Complications of HIV Infection Study Group. Ann Intern Med 1997, 126:123-132.
15. Guelar A, Gatell JM, Verdejo J, Podzamczer D, Lozano L, Aznar E, et al. A prospective study of the risk of tuberculosis among HIV- infected patients. AIDS 1993, 7:1345-1349.
16. Ancelle-Park RA, Alix J, Downs AM, Brunet JB. Impact of 1993 revision of adult/adolescent AIDS surveillance case-definition for Europe. National Coordinators for AIDS Surveillance in 38 European countries [letter]. Lancet 1995, 345:789-790.
17. Geskus RB. Methods for estimating the AIDS incubation time distribution when date of seroconversion is censored. Stat Med 2001, 20:795-812.
18. Gilks CF, Godfrey-Faussett P, Batchelor BI, Ojoo JC, Ojoo SJ, Brindle RJ, et al. Recent transmission of tuberculosis in a cohort of HIV-1-infected female sex workers in Nairobi, Kenya. AIDS 1997, 11:911-918.
19. Hawken M, Nunn P, Gathua S, Brindle R, Godfrey-Fausset P, Githui W, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993, 342:332-337.
20. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994, 330:1710-1716.
21. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993, 328:1137-1144.
22. Cayla JA, Garcia DOP, Galdos-Tanguis H, Vidal R, Lopez-Colomes JL, Gatell JM, et al. The influence of intravenous drug use and HIV infection in the transmission of tuberculosis [letter]. AIDS 1996, 10:1446-1447.
23. Sudre E Hirschel BJ, Gatell JM, Schwander JM, Vella S, Katlama C, et al. Tuberculosis among European patients with the acquired immune deficiency syndrome. Tuberc Lung Dis 1996, 77:322-328.
24. World Health Organization. Global Tuberculosis Control. Geneva: World Health Organization; 2002.
25. Leitch AG, Rubilar M, Watt B, Laing R, Willcocks L, Brettle RP, et al. Why disease due to Mycobacterium tuberculosis is less common than expected in HIV-positive patients in Edinburgh. Respir Med 1995, 89:495-497.
26. Jansa JM, Serrano J, Cayla JA, Vidal R, Ocana I, Espanol T. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis. Int J Tuberc Lung Dis 1998, 2:140-146.
27. Solera J, Lopez E, Serna E, Vergara L, Martinez-Alfaro E, Saez L. Risk of tuberculosis in parenteral drug addicts with human immunodeficiency virus seropositivity. A cohort study in detoxication communities. [In Spanish] Med Clin 1993, 100:725-729.
28. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. [Published erratum appears in JAMA 1992 268:3434.] JAMA 1992, 268:504-509.
29. Daley CL, Hahn JA, Moss AR, Hopewell PC, Schecter GF. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. Am J Resp Crit Care Med 1998, 157:19-22.
30. Kirk O, Gatell JM, Mocroft A, Pedersen C, Proenca R, Brettle RP, et al. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Resp Crit Care Med 2000, 162(suppl 3:Pt 1):t-72
31. Junghans C, Low N, Chan P, Witschi A, Vernazza P, Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999, 13:2547-2554.
32. Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, et al. A comparison of exposure groups in the EuroSIDA Study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 22:369-378.
33. Strathdee SA, Palepu A, Cornelisse PGA, Yip B, O'Shaughnessy MV, Montaner JSG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998, 280:547-549.
34. Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, et al. Why is highly active anti-retroviral therapy (HAART) not prescribed or discontinued? Swiss HIV cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 21:114-119.